<DOC>
	<DOCNO>NCT02481336</DOCNO>
	<brief_summary>To study risk prediction chemotherapy-induced peripheral neuropathy ( CIPN ) clinical bioinformatics genomic profile .</brief_summary>
	<brief_title>To Study Individual Variants Chemotherapy-Induced Neurotoxicity</brief_title>
	<detailed_description>This prospective , observational , cohort study , monitor chemotherapy-induced peripheral neurotoxicity traditional clinical scale , neurological examination , semi-quantitative assessment . Moreover , genetic change analyze next generation sequence try identify relevant variant individual suffer chemotherapy-induced neurotoxicity .</detailed_description>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>1 . Histologically confirm epithelial ovarian cancer , endometrial cancer adenocarcinoma colon rectum 2 . Pathological stage I~IV ovarian cancer , stage II~IV endometrial cancer stage III &amp; high risk stage II colorectal cancer 3 . Scheduled receive adjuvant Paclitaxel/Carboplatin ovarian endometrial cancer , mFOLFOX6 colorectal cancer 4 . Age ≥ 20 year old 5 . ECOG Performance status 01 6 . Adequate organ function Bone marrow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L WBC ≥ 3.0 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL Hepatic : Total bilirubin level ≤ 1.0 x UNL AST ALT ≤ 3.0 x UNL Renal : Creatinine level ≤ 1.5 mg/dL men , ≤1.4 mg/dL woman ; Estimated CCr ≥ 60 mL/min ( CCr estimate CockcroftGault formula , appendix III ) . 7 . Negative pregnancy test woman childbearing potential 8 . Patient willing provide blood sample research purpose 9 . Written inform consent 1 . Prior treatment neurotoxic chemotherapy , oxaliplatin , cisplatin , carboplatin , taxanes vinca alkaloid 2 . Receiving chemotherapy within 6 month 3 . History allergy 5FU LV 4 . Preexisting peripheral neuropathy grade 5 . A family history genetic familial neuropathy 6 . Active uncontrolled infection 7 . Significant medical disease , unstable angina , acute recent myocardial infarction ( &lt; 6 month enrollment ) , COPD frequent exacerbation , uncontrolled hypertension , ore cent CVA ( &lt; 6 month enrollment ) 8 . Poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Peripheral Neuropathy</keyword>
</DOC>